207 related articles for article (PubMed ID: 23570181)
1. SOP 05: Patient information and informed consent.
Onkologie; 2003 Oct; 26 Suppl 6():23-33. PubMed ID: 23570181
[No Abstract] [Full Text] [Related]
2. SOP 07: Data flow, monitoring, and archiving.
Onkologie; 2003 Oct; 26 Suppl 6():36-7. PubMed ID: 23570183
[No Abstract] [Full Text] [Related]
3. SOP 07a: Monitoring of a trial under CESAR responsibility.
Onkologie; 2003 Oct; 26 Suppl 6():38-40. PubMed ID: 23570184
[No Abstract] [Full Text] [Related]
4. SOP 08: Reporting of adverse events.
Onkologie; 2003 Oct; 26 Suppl 6():41-2. PubMed ID: 23570185
[No Abstract] [Full Text] [Related]
5. SOP 06: Selecting the participating centers and activation of a trial.
Onkologie; 2003 Oct; 26 Suppl 6():34-5. PubMed ID: 23570182
[No Abstract] [Full Text] [Related]
6. SOP 10: Study report and publication.
Onkologie; 2003 Oct; 26 Suppl 6():48-9. PubMed ID: 23570187
[No Abstract] [Full Text] [Related]
7. SOP 04: Data collection forms (case report forms).
Onkologie; 2003 Oct; 26 Suppl 6():15-22. PubMed ID: 23570180
[No Abstract] [Full Text] [Related]
8. SOP 09: Statistical design and analysis.
Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
[No Abstract] [Full Text] [Related]
9. SOP 14: Population pharmacokinetic analysis.
Onkologie; 2003 Oct; 26 Suppl 6():60-6. PubMed ID: 23570191
[No Abstract] [Full Text] [Related]
10. SOP 12: Validation of bioanalytical methods.
Onkologie; 2003 Oct; 26 Suppl 6():52-5. PubMed ID: 23570189
[No Abstract] [Full Text] [Related]
11. SOP 03: Preparation and structure of trial protocols.
Onkologie; 2003 Oct; 26 Suppl 6():11-4. PubMed ID: 23570179
[No Abstract] [Full Text] [Related]
12. SOP 13: Pharmacokinetic data analysis.
Onkologie; 2003 Oct; 26 Suppl 6():56-9. PubMed ID: 23570190
[No Abstract] [Full Text] [Related]
13. SOP 11: Quality assurance.
Onkologie; 2003 Oct; 26 Suppl 6():50-1. PubMed ID: 23570188
[No Abstract] [Full Text] [Related]
14. [Ethical and regulatory requirements for conducting clinical trials: patient information and patient informed consent].
Schwarz JA
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):429-37. PubMed ID: 15830254
[TBL] [Abstract][Full Text] [Related]
15. [Information to patient through an informed consent].
Giraldo P; Comas M; Sala M
Med Clin (Barc); 2015 Jul; 145(2):89-90. PubMed ID: 25190584
[No Abstract] [Full Text] [Related]
16. From a constitutional right to a policy of exceptions: Abigail Alliance and the future of access to experimental therapy.
Shah S; Zettler P
Yale J Health Policy Law Ethics; 2010; 10(1):135-96. PubMed ID: 20229846
[No Abstract] [Full Text] [Related]
17. [Attitude of patient associations to clinical trials of new drugs].
Tybkjaer HW; Witte L; Johannessen MB
Ugeskr Laeger; 2003 Apr; 165(16):1688-90. PubMed ID: 12756833
[TBL] [Abstract][Full Text] [Related]
18. Cancer drugs. Weighing the risks and benefits.
Bren L
FDA Consum; 2007; 41(1):10-9. PubMed ID: 17342832
[TBL] [Abstract][Full Text] [Related]
19. Next steps in clinical trial redesign.
Nicholas J
J Natl Cancer Inst; 2012 Jan; 104(2):90-2. PubMed ID: 22215851
[No Abstract] [Full Text] [Related]
20. SOP 02: Evaluation and selection of a clinical trial proposal for CESAR.
Onkologie; 2003 Oct; 26 Suppl 6():5-10. PubMed ID: 23570178
[No Abstract] [Full Text] [Related]
[Next] [New Search]
